Japan-based Takeda Pharmaceutical has entered a partnership with Cardurion Pharmaceuticals to develop new and advanced therapeutics for the treatment of cardiovascular diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cardurion is a newly formed US-based biotechnology company that focuses on the development of latest therapeutics to treat patients with heart failure or other cardiovascular diseases.

Under the new cardiovascular development partnership, Takeda will provide a 12-person cardiovascular research team from its Shonan, Japan site, to boost the discovery efforts made by Cardurion.

Takeda chief medical and scientific officer Dr Andrew Plump said: “The creation of this partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists into entrepreneurial environments.

See Also:

“By leveraging the high level of therapeutic expertise at Takeda’s Shonan Research Centre to support drug discovery, we’re motivating scientists to come together to deliver on our promise of serving patients with existing unmet needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The scientific collaboration we’re establishing with Takeda will propel our preclinical efforts and ultimately help get important therapies into the hands of patients in need."

Takeda will also provide the new company with fully equipped laboratory space, development resources and licences to range of preclinical-stage cardiovascular drug programmes.

Cardurion Pharmaceuticals chief executive officer Dr Daniel Bloomfield said: “This partnership demonstrates our shared commitment to developing transformative, novel therapies that can have a meaningful impact for the millions of people around the world suffering from heart disease.

“The scientific collaboration we’re establishing with Takeda will propel our preclinical efforts and ultimately help get important therapies into the hands of patients in need.”

Cardurion Pharmaceuticals is based in Cambridge, Massachusetts, US, and has research facilities in Shonan, Japan.

Image: Headquarters of Takeda Pharmaceutical Company in Chuo-ku, Osaka, Japan. Photo: courtesy of J o.